Evotec Signs High Throughput Screening Collaboration with Alios Biopharma
News Jul 22, 2009
Evotec AG has announced collaboration with Alios Biopharma, Inc in the area of high throughput screening (HTS).
Alios BioPharma, Inc. is a biotechnology company that is developing novel medicines that treat diseases in virology by activating pathways in the innate immune system.
Evotec will use its proprietary ultra-HTS platform and technology to screen a priority biological target for Alios. Evotec’s HTS technology has been developed in collaboration with its pharmaceutical partners Pfizer, Novartis and GSK. It combines an ultra sensitive detection technology with a miniaturized screening format. In addition, Alios will access Evotec’s high quality small molecule screening library for the screen.
Dr. Leonid Beigelman, Executive Vice President of Research, from Alios commented: “Evotec has compiled a small molecule screening library that provides excellent diversity and high quality. This, combined with their exceptional HTS technology makes them an ideal partner for screening our important target with the aim of finding high quality hits for our subsequent medicinal chemistry efforts.”
Evotec’s EVP, Business Development, Dr Mark Ashton commented on the collaboration: “We are pleased that Alios have chosen Evotec to provide HTS support for their important target. We are excited about identifying new hits for their program and supporting them in their quest for new treatments for virology diseases.”
No financial details are disclosed.
How do Poison Frogs Protect Themselves Against Their Own Neurotoxin?News
Scientists are a step closer to resolving a related head-scratcher, how do these frogs keep from poisoning themselves?READ MORE
Unchained Labs Unveils LEA 9 Software Making Workflows EasyNews
Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, released its LEA 9 software, making Freeslate and Junior automation systems way more accessible.READ MORE